drug value

Market Access

The journey to global market access for innovative therapies is fraught with challenges that vary significantly across the world.

Views & Analysis

Addressing the data and evidence gap in the early stages of asset development.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.